Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 358

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 358
---
 was Global Head of Infectious Diseases for J&J. Dr. Pomerantz has. Since February 2020, he served
as Chairman of Collplant Biotechnologies (Nasdaq: CLPT), since May 2022 he served as Vice Chairman of Enlivex Therapeutics Ltd.
(Nasdaq: ENLV), and was previously a member of the board of directors of Viracta (Nasdaq: VIRX) from June 2020 until December 2024,
Rubius Therapeutics (Nasdaq: RUBY) from 2014 to 2019 and Evelo Therapeutics (Nasdaq: EVLO) from 2015 to 2016. Dr. Pomerantz earned his B.A. in biochemistry at the Johns Hopkins University and his M.D. at
the Johns Hopkins School of Medicine. He completed his internal medicine internship and residency training, and his subspecialty
clinical and research training in infectious diseases and virology at the Massachusetts General Hospital of Harvard Medical School.
His post-doctoral research training in molecular retrovirology was obtained at both Harvard Medical School and the Whitehead
Institute of the Massachusetts Institute of Technology (MIT). Dr. Pomerantz also served as the Chief Resident at the Massachusetts
General Hospital. Following his medical-scientist training, he was an Endowed, Tenured Professor of Medicine and Molecular
Pharmacology and Chairman of the Infectious Diseases Department of Thomas Jefferson University in Philadelphia. Dr. Pomerantz is an
internationally recognized expert in HIV molecular pathogenesis and latency. He has developed ten approved infectious disease drugs
in important diseases including HIV, HCV, tuberculosis, and Clostridium difficile infection. We believe Dr. Pomerantz is qualified
to serve on our board of directors because of his significant scientific, executive and board leadership experience in drug
development and in the pharmaceutical industry.

Hila
Karah has served on our board since July 2021 and previously served as a member of Intec Israel’s board of directors since
December 2009 until the Merger. Ms. Karah is a managing Partner of Pitango HealthTech VC and an experienced board director. Prior to
Pitango she served as an independent business consultant to private and public companies on strategy, operations, financing, regulatory
and corporate governance. From 2006 until 2013, Ms. Karah was the chief investment officer of Eurotrust Ltd., a family office, where